Should You Buy Eli Lilly Amid Its 15.6% Decline? Consider a Low-Cost Vanguard ETF

Eli Lilly, a drugmaker, is down 15.6% YTD, weighing on the healthcare sector. Its valuation is heavily dependent on maintaining its industry-leading position in the weight-loss drug space. A low-cost Vanguard ETF, Vanguard Healthcare ETF, has a 12.6% weighting in Lilly and diversified exposure to various healthcare stocks, making it a good value.